Waters Corporation
WAT
$332.19
+0.90%
Waters Corporation is a leading provider of analytical instruments and software, specializing in liquid chromatography, mass spectrometry, and thermal analysis tools used in life sciences, pharmaceutical, and industrial markets. The company is a market leader in high-performance liquid chromatography and mass spectrometry, distinguished by its premium product portfolio and deep scientific expertise. The current investor narrative is dominated by the transformative merger with BD's life science and diagnostics business completed in early 2026, which shifts Waters' business mix towards higher-growth diagnostics and life science tools, creating both significant integration opportunities and execution risks that are central to the stock's debate.…
WAT
Waters Corporation
$332.19
WAT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $431.85 and implied upside of +30.0% versus the current price.
Average Target
$431.85
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$266 - $432
Analyst target range
Waters is covered by 13 analysts, and the institutional rating actions show a consensus leaning neutral to cautiously optimistic, with recent actions including a mix of 'Hold', 'Equal Weight', 'Neutral', and a few 'Buy' or 'Outperform' ratings. The average analyst revenue estimate for the coming period is $8.36 billion, with a tight range between $8.20 billion and $8.45 billion, indicating strong consensus on the top-line outlook post-merger. The target price range and implied upside are not explicitly provided in the data, but the narrow revenue estimate band and the prevalence of neutral ratings suggest analysts see the stock as fairly valued at current levels, with the primary debate centered on successful integration execution rather than fundamental disagreement on the financial model.
Bulls vs Bears: WAT Investment Factors
The evidence currently tilts bearish, as the stock's severe underperformance, margin pressure, and decelerating growth present immediate, quantifiable headwinds that outweigh the potential long-term benefits of the BD merger. The bullish case rests heavily on the successful integration and synergy realization from that merger, which remains unproven. The single most important tension in the investment debate is the execution risk of the transformative BD merger versus its promised acceleration into higher-growth diagnostics markets. The resolution of this integration—either through demonstrated cost savings and revenue synergies or through missteps and cultural clashes—will be the primary driver of the stock's direction over the next 12-18 months.
Bullish
- Strong Profitability & Cash Flow: Waters maintains robust profitability with a Q4 2025 gross margin of 59.79% and generated $539.8 million in trailing twelve-month free cash flow. This strong cash generation provides a solid foundation to fund the BD merger integration and navigate market volatility.
- Attractive Forward Valuation: The stock trades at a forward P/E of 20.10x, a significant discount to its trailing P/E of 35.17x, implying the market expects substantial earnings growth. This forward multiple, while above some sector peers, is reasonable for a market leader if merger synergies materialize.
- Solid Financial Health: The company's balance sheet is strong, with a manageable debt-to-equity ratio of 0.55 and a high return on equity of 25.09%. This financial stability reduces risk during the post-merger integration phase and provides flexibility for strategic investments.
- Transformative Merger Potential: The recent merger with BD's life science and diagnostics business diversifies Waters into higher-growth markets. Analyst consensus revenue estimates of $8.36 billion for the coming period reflect confidence in the combined entity's top-line potential.
Bearish
- Severe Underperformance vs. Market: WAT has dramatically underperformed, with a 1-year price change of -6.37% versus the S&P 500's +25.19%, resulting in a -31.55% relative strength. This persistent weakness indicates deep-seated investor skepticism, likely tied to merger execution risks.
- Profit Margin Compression: The company's net margin contracted from 26.51% in Q4 2024 to 24.16% in Q4 2025. This 235 basis point decline signals rising costs or pricing pressures, which could threaten earnings growth and the premium valuation.
- Revenue Growth Deceleration: Q4 2025 revenue growth slowed to 6.83% YoY, a deceleration from prior periods. This suggests core demand may be normalizing, raising questions about whether the merger can sufficiently re-accelerate top-line expansion.
- High Volatility & Downside Risk: With a beta of 1.141 and a maximum drawdown of -31.32% over the period, the stock is more volatile than the market and has proven susceptible to sharp declines. The 52-week low of $275.05 represents a -16% downside from the current price.
WAT Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -6.37% as of May 15, 2026, significantly underperforming the broader market. The current price of $329.22 sits approximately 21% above its 52-week low of $275.05 and 20% below its 52-week high of $414.15, positioning it in the lower half of its annual range, suggesting it is in a recovery phase from deeply oversold levels but remains under significant pressure. Recent momentum shows a stark divergence, with a 1-month gain of 0.93% and a 3-month gain of 1.81%, indicating a tentative stabilization or short-term bounce, yet this pales in comparison to the 6-month decline of -13.23%, signaling the nascent recovery lacks conviction and is occurring within a broader bearish context. Key technical support is clearly defined at the 52-week low of $275.05, while resistance lies at the 52-week high of $414.15; a sustained break below support would signal a continuation of the downtrend, whereas reclaiming the $350-$360 zone is necessary for a more constructive outlook. With a beta of 1.141, the stock is approximately 14% more volatile than the S&P 500, which is notable given its recent underperformance, indicating it has been a source of amplified downside risk for investors.
Beta
1.14
1.14x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
-7.6%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +1.3% | +4.0% |
| 3m | +3.3% | +8.2% |
| 6m | -11.7% | +11.5% |
| 1y | -7.6% | +24.3% |
| ytd | -13.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Revenue growth has been positive but is showing signs of deceleration; the most recent quarterly revenue (Q4 2025) was $932.4 million, representing a year-over-year growth of 6.83%, which is a slowdown from the stronger growth rates seen in prior comparable periods, indicating a potential normalization of demand post-pandemic. The company remains solidly profitable, with Q4 2025 net income of $225.2 million and a gross margin of 59.79%; however, the net margin of 24.16% for the quarter represents a compression from the 26.51% net margin in Q4 2024, reflecting some pressure on profitability amidst the integration of the BD acquisition. Financial health is robust, with a trailing twelve-month free cash flow of $539.8 million, a manageable debt-to-equity ratio of 0.55, and a strong return on equity of 25.09%, indicating the company generates substantial cash to fund operations and growth while maintaining a balanced capital structure with efficient use of shareholder capital.
Quarterly Revenue
$932362000.0B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$539810000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 35.17x and a forward PE of 20.10x; the significant gap implies the market expects a substantial recovery in earnings over the next twelve months, likely tied to synergies from the recent merger. Compared to sector averages, Waters trades at a premium; its forward PE of 20.10x is above typical industry multiples for life science tools, which often range in the mid-to-high teens, suggesting the market is pricing in superior growth and margin profile from its leading market position and the accretive BD merger. Historically, the current trailing PE of 35.17x is below the stock's own 5-year historical range, which has seen peaks above 80x during the pandemic, indicating the valuation has contracted significantly and may reflect a more reasonable entry point if the company's growth trajectory re-accelerates as anticipated.
PE
35.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 22x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is profit margin compression, with the net margin falling 235 bps YoY in Q4 2025 to 24.16%. This erosion, if sustained, could jeopardize the earnings growth implied by the forward P/E of 20.1x. Furthermore, while debt is manageable at a D/E of 0.55, the company faces integration costs and potential revenue dis-synergies as it absorbs the BD business. Revenue concentration risk is now heightened as the merger shifts the mix towards the untested (for Waters) diagnostics segment, creating dependency on successful cross-selling and market penetration.
Market & Competitive Risks: Valuation risk is pronounced; the forward P/E of 20.1x trades at a premium to many life science tool peers, leaving the stock vulnerable to multiple compression if growth disappoints. The stock's beta of 1.141 indicates it is 14% more volatile than the market, which has recently manifested as amplified downside, as seen in its -31.32% max drawdown. Competitive risks are elevated as Waters integrates into the diagnostics arena, competing with entrenched players while managing internal cultural and operational integration challenges that could distract from core R&D and sales execution.
Worst-Case Scenario: The worst-case scenario involves a botched merger integration, where expected cost synergies fail to materialize and revenue dis-synergies emerge, leading to further margin compression and growth stagnation. Concurrently, a broader market downturn compresses valuation multiples for premium-priced stocks. This could trigger a re-test and break below the 52-week low of $275.05. From the current price of $329.22, this scenario implies a realistic downside of approximately -16%. A more severe bear case, factoring in loss of confidence and analyst downgrades, could see the stock fall toward the $250-$260 range, representing a potential loss of -20% to -24%.
